ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1711

Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis

Andrew McGucken1, Flavia Sunzini2, Kristian Stefanov1, Joel Parkinson1, Salim Al-Wasity1, John McLean1, Gordon Waiter3, Stefan Siebert1 and Neil Basu4, 1University of Glasgow, Glasgow, United Kingdom, 2Glasgow University, Glasgow, United Kingdom, 3University of Aberdeen, Aberdeen, United Kingdom, 4Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

Meeting: ACR Convergence 2025

Keywords: Brain, Fatigue, Inflammation, Neuroimaging, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

Session Type: Abstract Session

Session Time: 3:15PM-3:30PM

Background/Purpose: Fatigue is a pervasive and burdensome symptom for people with psoriatic arthritis (PsA). The mechanisms underlying PsA related fatigue are unknown. In other clinical populations, the brain’s insula region, a key integration hub between peripheral signals of pain/inflammation and central signals such as mood, has emerged as a key component of the fatigue network1. Moreover, excess levels of brain glutamate has been implicated with this symptom2. To date, no studies have specifically examined the potential role of brain connectivity and glutamate in PsA fatigue.

Methods: Patients with active PsA who fulfilled the CASPAR criteria were evaluated. Fatigue was measured using a fatigue numeric rating scale averaged over the prior week (7-day fatigue NRS). Subjects then undertook functional MRI and single voxel MRI spectroscopy brain scans. Images were acquired using 3 Tesla Siemens PRISMA with 32-channel phased array head coil using a T2*-weighted gradient-echo echo-planar imaging pulse sequence. Functional MRI data was analyzed using functional connectivity CONN toolbox employing a right posterior insula seed. The functional connectivity of this region of interest to the whole brain was estimated, followed by group level multiple linear regression to 7-day fatigue NRS corrected for age, sex and multiple comparisons (FDR< 0.05). Right posterior insula spectroscopy data was analyzed using LCModel. Individual glutamate/glutamine concentrations were calculated and corrected for levels of brain creatine (Glx/Cr). Glx/Cr correlation with fatigue scores and insula seed functional connectivity was assessed.

Results: 38 enrolled patients completed both functional MRI and MRI spectroscopy (mean age 46.7 ± 9.9; 47% female; mean BMI 29.2 ± 4.6; mean 7-day fatigue NRS 6.4 ± 2.8; mean DAPSA 38 ± 15.8). Higher fatigue scores correlated with higher functional connectivity from the right posterior insula to cerebellum (R=0.694, p< 0.022FDR) and anti-correlated with functional connectivity to the superior frontal gyrus, which covers the medial prefrontal cortex (R=-0.7029, p=0.0008FDR) (Figure A). PsA patients with higher fatigue scores also trended towards increased Glx/Cr (R=0.3, p=0.07) in the right posterior insula and these levels significantly correlated with fatigue associated functional connectivity of this region (cerebellum: R=0.49, p=0.003 and superior frontal gyrus: R=-0.4, p=0.016) (Figure B).

Conclusion: We demonstrate for the first time that the brain may have a role in PsA fatigue. Specifically, the multifaceted role of the insula is highlighted. Altered functional connectivity between the posterior insula to brain regions involved in movement, motivation, and peripheral sensations (cerebellum); and executive decision making/emotions (superior frontal gyrus) appears to characterize fatigue severity in PsA. Excess of the excitatory neurotransmitter glutamate within the posterior insula may mediate this neural dysfunction but further research is warranted to understand it’s functional role and clarify its potential as a future therapeutic target for PsA fatigue.

Supporting image 1Figure A shows significant altered functional connectivity that correlates with fatigue scores. The top panel demonstrates the insula seed used for the seed-to-voxel analysis. The images show the voxel positions (colored area on brain slice) with slice number (Z) at the top of each image. The scatterplots visualize the correlation of functional connectivity (Fischer z-transformed r values) between two brain regions and fatigue scores, Pearsons R, and p values after false discovery rate for multiple comparisons (FDR). The tables demonstrate results from multi-linear modelling (correcting for age and sex), degrees of freedom (df), peak voxel co-ordinates in MNI space (x,y,z), and cluster size.

Supporting image 2Figure B shows (top left) the average position across all participants of 20x20x20mm voxel for the right posterior insula used in this analysis. The top right figure demonstrates right posterior insula glutamate/glutamine levels correlation of creatine (Glx/Cr) with 7-day fatigue scores. Bottom scatterplots illustrate right posterior insula functional connectivity correlating with right posterior insula Glx/Cr levels.


Disclosures: A. McGucken: None; F. Sunzini: None; K. Stefanov: None; J. Parkinson: None; S. Al-Wasity: None; J. McLean: None; G. Waiter: None; S. Siebert: AbbVie, 6, Amgen, 6, AstraZeneca, 6, BMS, 5, Boehringer-Ingelheim, 5, Eli Lilly, 5, GlaxoSmithKlein, 5, Johnson & Johnson, 5, 6, Novartis, 6, Pfizer, 6, Syncona, 6, Teijin Pharma, 6, UCB, 5, 6; N. Basu: AbbVie, 6, AstraZeneca, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, GSK, 2, 5, MSD, 2, Nesos, 5, Pfizer, 5, 6, Roche, 2, 6, Vifor, 2, 5, 6.

To cite this abstract in AMA style:

McGucken A, Sunzini F, Stefanov K, Parkinson J, Al-Wasity S, McLean J, Waiter G, Siebert S, Basu N. Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/dysfunctional-neurobiology-of-the-insula-characterizes-fatigue-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dysfunctional-neurobiology-of-the-insula-characterizes-fatigue-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology